Dacomitinib has not been approved by any regulatory agency.

Rolapitant has not been approved by any regulatory agency.

It was first developed by the pharmaceutical company Gilead to treat Ebola.

The Mortality rate for Zmapp and remdesivir were 49% and 53% respectively.

In contrast, 49 per cent on ZMapp and 53 er cent on Remdesivir died in the study, the agency said.

In contrast, 49 percent on ZMapp and 53 percent on Remdesivir died in the study, the agency said.

Gilead Sciences, Inc., developed remdesivir, also known as GS-5734, and collaborated in the research.

In contrast, 49 percent on ZMapp and 53 percent on Remdesivir died in the study, the agency said.

In contrast, 49% on ZMapp and 53% on Remdesivir died in the study, the agency said.

The Mortality rate for Zmapp and remdesivir were 49% and 53% respectively.

Nubia is only the second person worldwide to be given Remdesivir.

Remdesivir has previously protected animals against a variety of viruses in lab experiments.

The mortality rate for the other two drugs was higher — 49 percent for ZMapp and 53 percent for Remdesivir.

A total of 56 patients have been treated with mAb 114, remdesivir, ZMapp or Regeneron monoclonal antibodies.

In contrast, 49% on ZMapp and 53% on Remdesivir died in the study, the agency said.